New shorter radiation regimen aims to cut treatment time for head and neck cancer patients
NCT ID NCT07507058
First seen Apr 06, 2026 · Last updated Jun 22, 2026 · Updated 15 times
Summary
This phase II trial is testing a shorter, higher-dose radiation schedule (hypofractionated radiotherapy) for people with intermediate-risk head and neck cancer who have had surgery. The goal is to see if this 3-week course is safe and effective at controlling the cancer while possibly reducing side effects. The study will enroll 60 adults with stage II-IVA head and neck squamous cell carcinoma.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Hypofractionated radiotherapy (higher-dose radiation given over 3 weeks instead of the usual longer course)
What this could lead to
If successful, this could offer a more convenient and potentially less toxic radiation option for patients with intermediate-risk head and neck cancer after surgery.
What could go wrong
This is a small, early-phase trial (60 participants) with no comparison group, so results may not apply broadly. The higher daily radiation dose could increase late side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.